Your Search Returned 247 tagged news reports
In this video, health-care analysts David Williamson and Max Macaluso dive back in to the growing diabetes treatment market to focus on Novo Nordisk . They discuss the company's competitive position and management's assertion that new competition
Denmark based Novo Nordisk ( NVO ) recently announced that it will terminate the development of its phase III hemophilia candidate, vatreptacog alfa. Vatreptacog alfa, a fast-acting recombinant factor VIIa analogue, was being developed for
I look forward to see many more children benefiting from this program in coming days. I congratulate all those who are part of this initiative and wish all the very best."
Certainly, shareholders agree, with the stock having jumped nearly 60% in the past year. Novo is a pharmaceutical stock with a key focus on treating diabetes. As the incidence of diabetes has risen in the U.S. and elsewhere, Novo's insulin and blood-
Gonopolsky is among cardiac patients testing an energy-enhancing substance meant to improve stamina. Like a dream patient conjured up in the boardroom of a pharmaceutical company, the Russian grandmother accepted the risks of the drug she was taking
Camilla Rossil and Benny Schatz have been living with diabetes for several decades...I marked my 30th anniversary with diabetes this year and I invited my friends and family to champagne brunch just to celebrate, she said...Rossil, 35, was diagnosed
Charlie Kimball was diagnosed with Type 1 diabetes in 2007, news that upended his personal and professional life. But the 27-year-old English-born, California-raised open-wheel racing veteran didn't just work to get his career back on track, he's
Nestle, which accounts for more than 3 per cent of the Stoxx Europe 600 Index, advanced 2.4 per cent as higher prices helped to increase revenue. Novo Nordisk A/S gained 1.3 per cent after the company raised its full-year sales and profit forecasts.
Denmark (AP) — Danish pharmaceutical company Novo Nordisk A/S says its net profit grew by 29 percent in the second quarter of 2012, chiefly spurred by strong sales of its new diabetes drugs. The world's biggest insulin maker says
According to the Center for Disease Control (CDC), there are currently 26 million people living with diabetes, and 79 million people with pre-diabetes. To promote awareness about the scale of the challenge, Novo Nordisk has launched the Changing